Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

We continue to work closely with our partner to enable a seamless ... immunologic comparisons to establish non-inferiority ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

The candidate vaccines are part of Novavax's portfolio of recombinant protein-based vaccines ... the ID-UTI measure can be ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, according ...

More doctors are looking out for the condition. But that’s not enough to explain the increase in the nation’s overall ...